Roche (SIX: RO, ROG; OTCQX: RHHBY), announced that the European Commission has approved Zelboraf (vemurafenib) as a monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, the most aggressive form of skin cancer. Zelboraf is designed to target and inhibit mutated forms of the BRAF protein found in about half of all cases of melanoma.
Novartis announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has concluded the risk-benefit review of Rasilez and combination products containing aliskiren and confirmed it remains positive in the European Union (EU) for the treatment of essential hypertension. In addition, the CHMP has requested an update to the product information of Rasilez® (aliskiren) and combination products containing aliskiren available in the EU.
'Epilepsy In Our Time', a video diary, explores life with epilepsy from the perspective of those living with the condition on European Epilepsy Day - 13th February 2012. The disease is the most common serious brain disorder worldwide, affecting 6 million people in Europe(1). European Epilepsy Day is an initiative of the International Bureau for Epilepsy (IBE) and the International League Against Epilepsy (ILAE) and this year's theme is the burden of epilepsy.|
The country may well foster new models of innovation, but success will require a long-term commitment and talent development. Read more on the McKinsey Quarterly > |
Topics:
|
|
Dynamic domestic players and focused multinationals are helping China churn out a growing number of innovative products and services. Intensifying competition lies ahead; here’s a road map for navigating it. Read more on the McKinsey Quarterly > |
Topics:
|
|
Chinese innovation is evolving in diverse ways and at an uneven pace across a range of different industries. Presented here are ground-level views from three of them: automobiles, semiconductors, and pharmaceuticals. Read more on the McKinsey Quarterly > |
Topics:
|